NEW YORK (GenomeWeb) – NanoString Technologies said today that Anthem has issued a positive coverage decision for its US Food and Drug Administration-cleared Prosigna breast cancer assay.
According to NanoString, the payors decision reflects updated guidelines released this February by the American Society of Clinical Oncology, which endorse the use of Prosigna — and other similar tests — to guide adjuvant therapy decisions in women with certain early-stage invasive breast cancers.
Commercialized based on an academically developed gene expression classifier called PAM50, Prosigna runs on NanoString's nCounter Dx Analysis System — providing a risk category and numerical score reflecting a patient's 10-year risk of disease recurrence.
The company said that with the decision by Anthem, Prosigna is now covered by every national commercial insurance plan in the US, along with a majority of regional plans.
"We now estimate that over 95 percent of US patients that are indicated for Prosigna are covered, and our team continues to work with the remaining regional plans to ensure that their patients have access to this state-of-the-art test," NanoString President and CEO Brad Gray said in a statement.
During the second quarter of this year, NanoString said it saw record revenues from Prosigna with 11 new labs adopting the diagnostic.